Poly(lactic-co-glycolic) Acid/Solutol HS15-Based Nanoparticles for Docetaxel Delivery

Area of Science:

• Nanotechnology
• Materials Science
• Pharmacology

Background:

• Docetaxel (DCT) is a key anti-mitotic chemotherapy agent used for treating gastric, head and neck, breast, and prostate cancers.
• Poly(lactic-co-glycolic) acid (PLGA) is a biocompatible and biodegradable polymer, while Solutol HS15 is a nonionic solubilizer and emulsifying agent.
• Effective drug delivery systems are crucial for enhancing chemotherapy efficacy and minimizing side effects.

Purpose of the Study:

• To fabricate and characterize Poly(lactic-co-glycolic) acid/Solutol HS15-based nanoparticles (NPs) for docetaxel (DCT) delivery.
• To evaluate the potential of these NPs as a local anticancer drug delivery system.
• To investigate the role of Solutol HS15 in drug release kinetics.

Main Methods:

• Fabrication of PLGA/Solutol HS15/DCT NPs using a modified emulsification-solvent evaporation method.
• Characterization of NPs including mean diameter, size distribution, zeta potential, and morphology.
• In vitro drug release studies at physiological pH.

Main Results:

• PLGA/Solutol HS15/DCT NPs were successfully prepared with a mean diameter of approximately 169 nm, narrow size distribution, negative zeta potential, and spherical shape.
• Solid-state studies confirmed the dispersion and amorphization of DCT within the PLGA matrix.
• In vitro release tests indicated that the emulsifying property of Solutol HS15 enhanced docetaxel release at physiological pH.

Conclusions:

• The developed PLGA/Solutol HS15-based nanoparticles demonstrate successful docetaxel encapsulation and amorphization.
• The formulation exhibits favorable physicochemical properties for drug delivery.
• These nanoparticles represent a promising platform for local anticancer drug delivery, potentially improving cancer therapy outcomes.